• Addition of darolutamide to ADT, docetaxel extends survival in prostate cancer subset

    1 month ago - By Healio

    The addition of darolutamide to docetaxel and androgen deprivation therapy significantly prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to topline results of the randomized phase 3 ARASENS trial.
    Darolutamide , an oral androgen receptor inhibitor, features a distinct chemical structure that competitively inhibits androgen binding, androgen receptor nuclear translocation and androgen receptor-mediated transcription.
    The agent received FDA approval in July 2019 for treatment of men with nonmetastatic castration-resistant prostate cancer.
    Read more ...